The NCCN Oncology Research Program (ORP) strives to improve the quality of life for patients and reduce cancer-related deaths by advancing cancer therapies through research. Since the program’s establishment in 1999, the NCCN ORP has brought millions of dollars in research grants to investigators at NCCN Member Institutions. Research grants are provided to NCCN through collaborations with pharmaceutical and biotechnology companies; these grants are in turn used to support scientifically meritorious cancer research efforts.
NCCN ORP studies typically explore new avenues of clinical investigation and seek answers to important cancer-related questions. All studies are approved and funded through a scientific peer-review process and are overseen by the ORP.
This feature highlights an NCCN study funded through the grant mechanism.
A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non–Small Cell Lung Cancer
Principal Investigator: Ramaswamy Govindan, MD
Institution: Washington University School of Medicine
There has been limited benefit with angiogenesis inhibitor drugs in patients with non–small cell lung cancer (NSCLC). This study proposes that patients who are molecularly selected for treatment based on the presence of mutations (VEGFR1-3, PDGFR-A, PDGFR-B, and FGFR1-3) will have clinically meaningful benefits with nintedanib in terms of response rate (RR) and progression-free survival (PFS). Furthermore, this investigation plans to perform exome sequencing of paired tumor (pretreatment and posttreatment) to better define molecular marker predictors for response and resistance.
Evaluate RRs in patients with advanced NSCLC with mutations in the target genes for nintedanib
Correlate outcomes with specific mutations
Further evaluate extreme responders with exome and transcriptome sequencing